Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Liquid Supplement/Beverage Guidance Defines Distinctions

This article was originally published in The Tan Sheet

Executive Summary

The CFSAN guidance goes into greater detail on distinguishing liquid supplements from beverages, addressing stakeholders’ complaint about a 2009 draft. “This tends to really draw a bright line between the two different categories,” says CRN Regulatory Counsel Rend Al-Mondhiry.

Advertisement

Related Content

Dr. Oz Grilling In Senate Tops 2014 Dietary Supplement News
Dr. Oz Grilling In Senate Tops 2014 Dietary Supplement News
Relaxation Potion Warning: Wake Up Call About FDA Beverage Guidance
Relaxation Potion Warning: Wake Up Call About FDA Beverage Guidance
FDA Says Added Food Ingredients May Exceed GRAS Parameters
FDA Says Added Food Ingredients May Exceed GRAS Parameters
FDA Should Not Judge A Liquid Supplement By Its Packaging - Stakeholders
FDA Supplement Beverage Guidance May Open Can Of Regulatory Worms

Topics

Advertisement
UsernamePublicRestriction

Register

PS107044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel